Indonesia Home Infusion Therapy Market

Indonesia Home Infusion Therapy Market Executive Summary

The Indonesia Home Infusion Therapy market is at around $215.8 Mn in 2023 and is projected to reach $372.2 Mn in 2030, exhibiting a CAGR of 8.1% during the forecast period.

Medical treatment at hospitals and clinics for patients suffering from chronic diseases is not only expensive in the long run, but also inconvenient and cumbersome which ultimately leads to reduced quality of life. As a result, home infusion therapy has evolved as a comprehensive medical treatment which provides an alternative to the in-patient healthcare which is both affordable and convenient for the patients. Home infusion therapy refers to the administration of medications through a needle or catheter to patients at a place other than hospitals and clinics, usually their homes. Home infusion is frequently advised when oral medications are ineffective and when there is a strong need for parenteral administration of drugs. “Infusion therapy” usually refers to the intravenous administration of a medicine, but it can also describe circumstances in which alternative non-oral drug delivery methods, such as intramuscular injections and epidural routes, are used. Prescription drug therapies commonly administered via infusion therapy include antibiotic, antifungal, antiviral, chemotherapy, hydration, pain management and parenteral nutrition. Specialty infusion therapies can also be used to treat autoimmune deficiencies, multiple sclerosis, rheumatoid arthritis, cancer, congestive heart failure, haemophilia, and other disorders. A home infusion therapy provider is state-licensed pharmacy that is specialized in providing such treatment to patients in their homes or other alternative sites. An infusion therapy is only initiated upon the permission of a licensed physician who is supervising the patient’s care. To ensure safety and efficacy of the treatment, various services are performed by the healthcare givers include, but are not limited to, patient assessment and education, maintenance of appropriate documentation, adverse effect and drug interaction monitoring, and lastly, quality control of all the infusion medication and equipment.

Indonesia faces a significant challenge in managing the burden of chronic diseases on its healthcare system, which has directly led to increased rates of morbidity and mortality in the country. Therefore, the Indonesia Home Infusion Therapy Market is driven by significant factors such as the rising prevalence of chronic diseases, expanding geriatric population, and technological advancements. However, uncertain reimbursement policies, limited availability of nurses, and infrastructure and accessibility issues restrict the growth and potential of the market.

The major players of the Indonesia Home Infusion Therapy Market are Terumo Corporation, Nipro Corporation, Baxter International, ICU Medical (Smiths Medical), Becton, Dickinson and Company (BD), and Fresenius Kabi, among others.

Market Dynamics

Market Growth Drivers

Rising Prevalence of Chronic Diseases: Home infusion is a safe and effective method to manage the rising cases of chronic conditions as it is convenient which leads to improved patient adherence and treatment outcomes. For example, chemotherapy medications can be safely given to cancer patients at home, which lowers hospital stays and enhances patient comfort while receiving treatment. For patients with extensive diabetes care needs, insulin or other drugs can also be administered at home by infusion. Consequently, there is an increasing need for novel and efficient treatment approaches due to the increased prevalence of chronic illnesses. Because of its affordability, flexibility to different chronic conditions, and ease of use, home infusion therapy is becoming more and more popular as a means of managing chronic illnesses and enhancing patient quality of life, which is driving the market’s overall expansion.

Expanding Geriatric Population: According to the WHO data of 2022, Indonesia is regarded as an aging nation, with 6.53% of the total population covered by individuals aged 65 and above. People are more prone to long-term illnesses including diabetes, heart failure, and autoimmune disorders as they age. Many times, these illnesses necessitate long-term care using drugs that may be efficiently administered at home via infusion therapy. Moreover, the aging population is marked by a decline in mobility, which makes regular hospital visits difficult. A practical substitute is home infusion therapy, which enables patients to receive treatment in the comfort of their own homes, enhancing their quality of life and lessening the strain on caregivers. Furthermore, hospital environments can raise the risk of infection for older persons, who are more vulnerable to illnesses. However, home infusion therapy can improve patient outcomes by lowering the chance of contracting infections acquired outside of a hospital. The market for home infusion therapy is ultimately driven by the number of potential patients who may need it to manage chronic diseases, which is generally increased with the aging population.

Technological advancements: The home infusion therapy market is expected to grow at a high rate due to the numerous advantages that technological advancements provide. When compared to conventional intravenous infusion techniques, wearable infusion devices provide patients more flexibility and comfort by enabling continuous or long-term drug delivery subcutaneously. Improved insertion methods, a lower risk of infection, and longer wear periods are all provided by advanced catheter technologies, which increase patient comfort and treatment compliance. These technical developments result in better patient acceptance, a wider range of treatments, greater efficiency for medical professionals, and lower costs, all of which raise demand and fuel the market for home infusion therapy.

Market Restraints

Uncertain Reimbursement Policies: The varied and unclear reimbursement policies from private insurance companies and the government can limit patient access to home infusion therapy. Even though, home infusion therapy is much more affordable to patients rather than receiving in-patient care, there can be high costs associated with certain speciality infusion therapies. These high costs associated with specialty infusion treatment may discourage patients, especially those without adequate insurance coverage. Due to this, the Home Infusion Therapy Market gets affected as it faces resistance from the patients.

Limited Availability of Nurses: One of the major challenges of home infusion therapy is the shortage of trained nurses which results in fewer people being able to receive care at home and lengthier wait times. Prolonged wait times eventually prevents patients from using home infusion therapy and choose an alternative treatment. To attract and retain qualified healthcare professions, providers of home infusion therapy may need to offer higher salaries. This increases the operating expenses, which leads to overall high cost of the treatment, further restricting the market access. Thus, the Home Infusion Therapy Market is constrained by a lack of competent workers which ultimately slows the market growth.

Infrastructure and Accessibility Issues: In isolated or rural places, the availability of home infusion therapy services may be restricted. Patients who do not have access to qualified clinicians and necessary equipment for the home infusion therapy suffer. Additionally, the growth of home infusion therapy in some areas may not have sufficient cold chain logistics for the storage and transportation of temperature-sensitive drugs. As a result, this impacts the expansion of the home infusion therapy market as a whole.

Regulatory Landscape and Reimbursement Scenario

In Indonesia, the regulatory agency is called the National Agency of Drug and Food Control (NADFC), also known by its Indonesian name, Badan Pengawas Obat dan Makanan (BPOM) which operates under the Ministry of Health. It plays a critical role in ensuring the safety, efficacy, and quality of pharmaceuticals available in the nation.

The NADFC conducts detailed review and analysis of the applications from pharmaceutical companies to register and market the new drugs. It includes a thorough evaluation of the safety, efficacy, and quality of pharmaceutical products. After the NADFC is ensured of these characteristics, does it allow the drugs to be marketed. The NADFC is also responsible for post-marketing surveillance of the drugs in case of any reporting of adverse drug reactions.

Indonesia’s healthcare reimbursement system is a complex mix of public and private insurance schemes. The mandated national health insurance scheme in Indonesia is called Jaminan Kesehatan Nasional (JKN), or National Health Insurance. It attempts to give access to basic healthcare and covers a sizable section of the populace. The JKN reimburses healthcare costs for outpatient and inpatient services at the designated healthcare facilities. For the private sector, compared to the JKN, private health insurance plans may provide greater coverage and better reimbursement rates.

Competitive Landscape

Key Players

Here are some of the major key players in the Indonesia Home Infusion Therapy Market:

• Terumo Corporation
• Nipro Corporation
• Baxter International
• ICU Medical (Smiths Medical)
• Becton, Dickinson and Company (BD)
• Fresenius Kabi
• Option Care Health
• Medtronic
• B. Braun Melsungen AG
• CareFusion Corporation